Literature DB >> 6724253

Characteristics of colorectal carcinoma cells with high metastatic potential.

R S Bresalier, C R Boland, Y S Kim.   

Abstract

Malignant tumors shed large numbers of cells into the circulation, only a small fraction of which actually produce distant metastases. The cells comprising these tumors may be heterogeneous in many respects including their biological behavior. Inasmuch as colonic epithelial cells secrete mucins that reflect the state of cell differentiation, and differences in mucin structure may be detected by selective lectin binding, we used fluorescein isothiocyanate-conjugated lectins and fluorescence microscopy to analyze mucins secreted by primary colon cancers and metastases. In this way we hoped to determine whether differences exist in the glycoconjugates produced by metastatic and nonmetastatic cell populations. Out studies demonstrated that, in a given primary cancer, the mucin produced differed from that made by its metastases. Thus the vast majority of cells in primary tumors produced mucin that was specifically labeled by fluorescent peanut agglutinin (14 of 16 tumors). In contrast, 72% (37 of 51) of metastatic tumors produced mucin that did not bind peanut agglutinin (p less than 0.001). Colon cancer cells with high metastatic potential may therefore produce mucins that lack an exposed oligosaccharide receptor for this lectin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6724253

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

Review 1.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

2.  Molecular identification of lectin binding sites differentiating related low and high metastatic murine lymphomas.

Authors:  E Lang; V Schirrmacher; P Altevogt
Journal:  Clin Exp Metastasis       Date:  1988 Jan-Feb       Impact factor: 5.150

3.  Thomsen-Friedenreich (T)-active glycoproteins and a blood group N antigen precursor with T activity from human liver metastatic carcinomas.

Authors:  K Otsuka; S Ohkuma; T Nakajima; T Kudo
Journal:  Naturwissenschaften       Date:  1988-08

4.  Histochemical procedures for the simultaneous visualization of neutral sugars and either sialic acid and its side chain O-acyl variants or O-sulphate ester. I. Methods based upon the selective periodate oxidation of sialic acids.

Authors:  D Volz; P E Reid; C M Park; D A Owen; W L Dunn
Journal:  Histochem J       Date:  1987-05

5.  Histochemical procedures for the simultaneous visualization of neutral sugars and either sialic acid and its O-acyl variants or O-sulphate ester. II. Methods based upon the periodic acid-phenylhydrazine-Schiff reaction.

Authors:  C M Park; P E Reid; D A Owen; W L Dunn; D Volz
Journal:  Histochem J       Date:  1987-05

6.  A new method for the histochemical demonstration of O-acyl sugars in human colonic epithelial glycoproteins.

Authors:  P E Reid; D Volz; K Y Cho; D A Owen
Journal:  Histochem J       Date:  1988-09

7.  The clinical significance of regional variations in histologic differentiation within carcinomas of the colorectum.

Authors:  H Kotanagi; T Fukuoka; Y Shibata; T Yoshioka; O Aizawa; K Koyama
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

8.  Lectin histochemistry of nephroblastoma (Wilms' tumour).

Authors:  R A Hennigar; D A Sens; S S Spicer; B A Schulte; V Newman; M A Sens; A J Garvin
Journal:  Histochem J       Date:  1985-10

9.  A morphometric study of invasion and metastasis in human colorectal carcinoma.

Authors:  P H Watson; I Carr
Journal:  Clin Exp Metastasis       Date:  1987 Oct-Dec       Impact factor: 5.150

10.  Detection of metastasis-associated differences for receptors of glycoconjugates (lectins) in histomorphologically unchanged xenotransplants from primary and metastatic lesions of human colon adenocarcinomas.

Authors:  H J Gabius; T Ciesiolka; E Kunze; K Vehmeyer
Journal:  Clin Exp Metastasis       Date:  1989 Sep-Oct       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.